As a valued Relias Media subscriber, you can find the latest issue of your publication online. The articles below provide timely strategies and research for healthcare providers:
In this Phase I/IIa clinical trial, investigators administered antisense huntingtin oligonucleotides intrathecally to patients with early Huntington’s disease (HD), and demonstrated safety, tolerability, and dose-dependent reduction in CSF mutant huntingtin. This approach now is being tested for clinical efficacy in HD in a Phase III clinical trial.
In this multicenter Phase IIa clinical trial in mild Alzheimer’s disease dementia, the tyrosine kinase Fyn inhibitor AZD0540 had no significant effects after 52 weeks of treatment.
As a class, fluoroquinolones are some of the most commonly used antibiotics worldwide. Their use carries a significant risk of neurotoxicty, for both the peripheral and central nervous system.
Disparities of treatment for stroke across various ethnic and racial groups need to be examined carefully to ensure uniform application of this treatment.
The authors of this trial investigated the benefits and risks of early anticoagulation following acute ischemic stroke, and compared the effects of direct oral anticoagulants vs. vitamin K antagonists. Overall, treatment with direct oral anticoagulants resulted in a reduced risk of poor clinical outcomes, primarily due to reduced risk of intracerebral hemorrhage.
Endovascular reperfusion therapy has been demonstrated to be of benefit for the treatment of large vessel occlusion in patients with acute ischemic stroke.
Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; and Accreditations Manager Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.
